INTRODUCTION
With a worldwide prevalence of 9% among adults, type 2 diabetes (t2DM) is found to be a major pandemic with an estimate of 1.5 million deaths in 2012 1 2 . The disease is characterized by hyperglycemia caused by insulin resistance. It is known that weight loss can have a substantial positive effect. Maintenance of a stable weight can however be a serious endeavor in morbidly obese patients. It was stated in 2013 that diabetes at least doubles a person's mortality 3 .
Roux-en-Y gastric bypass (RYGB) is a popular bariatric intervention which was initially developed by Dr. Edward Mason in the 1960's. It has shown excellent mid-term weight loss results by combining food restriction (by the creation of a small stomach
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pouch) and relative malabsorption (intestinal bypass). A mid-term significant amelioration or even resolution of comorbidities is frequently seen in patients. Few studies evaluating the mid-term outcome of t2DM after RYGB are available at this time.
The aim of this study is to retrospectively analyze mid-term effects of RYGB on t2DM regarding the need for anti-diabetic medication (insulin dependency), alteration of biochemical parameters and associated weight loss in a single surgeon setting.
METHODS
Retrospective analysis of prospectively collected data was performed for patients suffering from t2DM (following current WHO criteria 4 Postoperative biochemical analysis was carried out by an endocrinologist (in strict cooperation with the general practitioner) with regular visits depending on the type of anti-diabetic medication (insulin dependent patients were suggested a more vigilant follow-up). In addition, a subdivision was made according to diabetic response over time: "remission" and "non-remission" (including "improvement", "aggravation" or "status-quo" (SQ)). Emphasis was put on the need for medication compared with baseline needs.
"Remission" of diabetes was defined as a fasting glucose of less than 126mg/dl and HbA1c of less than 6.5% without the need of anti-diabetic medication for at least 6 months. "Improvement" was defined as a reduced need for anti-diabetic medication compared with baseline needs, "aggravation" as a higher need and "status quo" as unchanged. Finally "relapse" was defined as a renewed need for medication after initial "remission" was achieved.
Interpretation of continuous data was performed using the F-test. Because some patients did not have their weights documented at each determined interval, lacking data was interpolated by replacing missing values with estimates generated using application of polynomial spline function. To obtain maximum significance, no spatial interpolation concerning diabetic evolution or glycemic parameters (fasting glucose, HbA1c) was used, only absolute data obtained from predetermined follow-up visits. Telephonic interviews were conducted to maximize mid-term follow-up data.
RESULTS
A total of 140 patients (97 women and 43 men) were included in our database (table 1 Overall patient follow-up data was moderate with a lost-in-follow-up (LIFU) ratio of 22.5% after 1 year, 30.9% after 3 years, 39.2% after 6 years and 42.9% after 10 years. Detailed attrition rate is illustrated in table 2.
Mid-term effect of
Postoperative weight loss was determined at each interval: 77.4%EWL after 1 year, 69.7%EWL after 3 years, 76.4%EWL after 6 years and 55.9%EWL after 10 years.
There was no significant difference in weight loss (BMI, %EWL) or mean fasting blood sugar between patients who experienced remission of diabetes and those who did not.
In patients with remission, a significantly lower HbA1c was reported at 6 and 10 years after surgery (P < 0.05). Complete stratified postoperative results are illustrated in table 3 . *SQ: status quo -no change in medication compared with baseline needs **aggravation: higher need for anti-diabetic medication (OAD and/or insulin) compared with baseline needs † improvement: reduced need for anti-diabetic medication (OAD and/or insulin) compared with baseline needs ‡ remission: fasting glucose of less than 126mg/dl and a hemoglobine A1c of less than 6.5% without the need of anti-diabetic medication for at least 6 months
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DISCUSSION
The various mechanisms and their individual potential in which RYGB positively influences type 2 diabetes are still under investigation 5 6 . Improvement of glucose homeostasis after RYGB is frequently seen even before significant weight loss is achieved 7 . It is believed that a complex alteration in gut hormones is responsible for this phenomenon 8 910 and therefore like it is showed in this study, remission of diabetes is not always significantly correlated with weight loss 11 12 .
Mid-term effect of Roux-en-Y gastric bypass on type 2 diabetes mellitus: a retrospective single surgeon observational study with focus on anti-diabetic medication Gys, B; et al
Our retrospective data analysis show a mid-term beneficial response of t2DM after RYGB in the majority of patients with an overall remission rate of 52.9% after 1 year, 55.1% after 3 years, 49.1% after 6 years and 41.7% after 10 years. Our results are slightly lower than other studies ranging from 26 -100% after 1 year, 81% after 3 years, 44 -88% after 5 years and 71 -89% after 10 years 13141516 . Attrition bias and variable definitions of "remission" in literature might be among the possible explanations for the variety in these numbers. Also, the majority of all cited studies is based on retrospective analysis with at least moderate lost-in-follow-up ratios, especially on mid-term base.
No significant correlation was found between diabetes remission and gender, preoperative duration of t2DM, baseline age, BMI, Hba1c or fasting glucose. Some studies however, did show significant correlation, especially for baseline HbA1c, age, preoperative use of insulin and/or disease duration 17 18 . Unfortunately, relapse of t2DM was present in 13.3%. Similar population-based studies showed relapses of 24.0 -43.1% correlated with female sex, early disease stage at the moment of surgery and/or a lower baseline BMI 19 20 .
Bariatric surgery is useful in the mid-term management of uncontrolled t2DM
in patients who are insulin dependent and those who are not. Relapse was observed in some patients and therefore we should be critical about mid-term durability. In literature, "remission" of t2DM can vary depending on the criteria 21 . We chose to focus on the use of medication rather than on biochemical parameters. In order to establish the real potential effects and their significance, more (prospective) analysis is necessary. In conclusion, bariatric surgery is useful in the mid-term management of uncontrolled t2DM.
